Revision summary
DBT, public labs, BIRAC, a large patient market, and generics plants explain India’s biotech bustle. Farm tools and contract research add demand besides hospitals. Biopharma gained vaccines, biosimilars, recombinant insulin, and diagnostics, including UN-prequalified shots. Gaps are original discovery, trial capital, and slow or split regulation. Policy should keep cheap quality biologics and add a cleaner, faster regulatory clock.
Model answer
Copper italics in this answer — like this — are the key facts. Each one is unpacked in the Facts & figures rail.
Introduction
Biotechnology uses living cells and tools of genetics to make drugs, seeds, enzymes, and diagnostics. India is busy in this field because it has low-cost scientific labour, a large patient and farm market, public labs, and a generics industry that can absorb new tools. Biopharma—vaccines, biosimilars, insulin, and diagnostics—has been the clearest commercial winner, though regulation and original discovery still lag.
Body
Why so much biotech activity
- Department of Biotechnology (DBT) (1986), CSIR labs, ICAR, and IITs built a public pipeline of skills; BIRAC later funded start-ups and industry–academia projects.
- A huge disease burden (vaccines, TB, diabetes, cancer biosimilars) and a huge agri-base (tissue culture, biofertilisers, Bt cotton) create domestic demand.
- English-speaking scientists, IT-enabled trial data, and contract research attract global firms to Indian labs and plants.
- Patent law after TRIPS pushed firms from only copying small-molecule drugs toward process skill, biosimilars, and vaccines where India could still compete.
- Start-up policy, biotech parks, and export of bulk enzymes and reagents added a private layer on the old public-lab base.
- Activity is also high because the problems are public: cattle vaccines, diagnostics for outbreaks, and seed stress under climate change cannot wait for imported kits alone.
Benefits to biopharma
- India is a major supplier of vaccines (including WHO-prequalified products for UN agencies): pentavalent, hepatitis B, rotavirus, and later other public-programme shots built on this base.
- Biosimilars of monoclonal antibodies and other biologics, plus recombinant insulin, cut treatment cost in India and in other developing markets compared with originator brands.
- Diagnostics (ELISA, molecular kits, later point-of-care) grew from the same skill set that serves hospitals and the ICMR network.
- Contract manufacturing and research for global pharma brought GMP plants, cold-chain discipline, and jobs in Hyderabad, Pune, Bengaluru, and Ahmedabad belts.
- Public programmes (universal immunisation, later Mission Indradhanush) gave a volume market that private biopharma could plan around.
- The sector still leans more on follow-on biologics and vaccines than on first-in-class molecules; that is a real benefit for access, not yet a Nobel-pipeline story.
Gaps
- Regulatory delay and overlapping DBT–CDSCO–GEAC lanes slow trials and GM as well as novel biologics.
- Venture capital, animal-house, and Phase-III capacity remain thinner than China’s or the US scale.
- Bt cotton showed farm biotech can spread fast; food GM remains politically stuck, which splits the sector’s energy.
- Data integrity and quality scares in some plants can stain the whole export brand.
Way forward
- One predictable regulator clock for clinical trials and biosimilar pathways, with world-class inspection rather than extra paper.
- Public purchase that rewards quality and new antigens, not only the lowest bid that kills R&D.
- BIRAC-scale funding for translational labs, cluster freeze-dry and fill-finish, and skill in bioprocess engineering.
- Open biopharma to ethical data-sharing for rare diseases while protecting privacy.
- Keep access as the Indian edge: cheap, good-enough biologics for the South, while a few centres chase original discovery.
Flow diagram
Conclusion
Biotechnology is busy in India because public science, a huge health and farm market, and a generics culture met global contract demand. Biopharma gained vaccines, biosimilars, insulin, and diagnostics that cut cost and serve immunisation. The next gain is faster clean regulation and more original biologics, without losing the access model.
Quick related
Students also ask
-
Among several factors for India's potential growth, savings rate is the most effective one. Do you agree? What are the other factors available for growth potential?
Next question on this syllabus topic (2017 · Q1). View answer →
-
Is Indian biotech only about GM food?
No. Vaccines, biosimilars, diagnostics, enzymes, and tissue culture are larger in jobs and exports than food GM, which remains limited.
-
Did biopharma only copy foreign drugs?
Much of the gain is process skill, vaccines, and biosimilars. That still lowered prices. First-in-class discovery is the unfinished part.
Same topic · past papers
UPSC has asked this before
These previous-year questions sit on the same topic. Open one to practise the earlier ask.
More from this topic
Q17 · UPSC Mains 2026 · GS III · 15 marks · Solution
What are the challenges to solid waste management in India? Discuss the governmental policy framework on solid waste management. Discuss the success/failure cases of Delhi and Indore cities highlighting the salient features of their solid waste management initiatives.
Indian Economy
• Challenges: volume growth, mixed waste, land, informal exclusion, weak finance. • SWM Rules 2016 mandate segregation, collection, processing, user fees. • Plastic/C&D/e-waste rules and SBM Urban complete the framework. • Swachh Survekshan creates competitive accountability. • Indore: strong segregation, collection, processing, enforcement. • Delhi: huge volumes, legacy dumps, fires, fragmented stress. • Lesson: behaviour + processing beat trucks-only strategies. • Biomining and bulk-generator compliance are essential for metros.
Q16 · UPSC Mains 2026 · GS III · 15 marks · Solution
What is Agentic Artificial Intelligence (AI)? Explain its working. Describe its applications with suitable examples. Discuss the advantages, risks and challenges associated with agentic AI systems.
Indian Economy
• Agentic AI pursues goals via plan–act–observe loops, not one-shot replies. • Working parts: planning, tools, memory, guardrails, stop conditions. • Uses: grievance assist, compliance, agri/disaster fusion, cyber SOCs, tutoring. • Advantages: speed, consistency, expert leverage, continuous monitoring. • Risks: harmful actions from hallucinations, injection attacks, privacy leaks. • India challenges: languages, liability, data law, compute cost, evaluation. • Govern with human approval for high stakes, logs and allow-listed tools. • Sandboxes beat unsupervised autonomy over money and rights.
Q15 · UPSC Mains 2026 · GS III · 15 marks · Solution
Mention salient features of 'Mission Drishti'. Discuss the imaging techniques used in the satellite launched on 3rd May 2026. Why is it being considered world's first satellite of its kind?
Indian Economy
• Mission Drishti is GalaxEye's EO satellite launched 3 May 2026. • Marketed as world's first OptoSAR combining optical + all-weather radar. • Described as India's largest privately built satellite in that category. • Imaging: X-band SAR (Stripmap/Spotlight) plus 7-band MSI. • Fusion on one platform avoids two-satellite parallax/time errors. • Fused resolution marketed near 1.8 m; SAR spotlight finer (~0.9 m claimed). • Orbit: sun-synchronous LEO ~500 km class; revisit ~4 days (company). • Novelty is integrated commercial OptoSAR—not inventing SAR/optical physics.